Direxion Daily Financial Bull 3X Shares ETF
FAS
Spdr S&P Bank Etf
KBE
Ultra Financials Proshares
UYG
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Aprea Therapeutics (APRE)
- 0.9110
- -0.0141-1.52%
Close Dec 16 16:00 ET
8.65MMarket Cap-0.43P/E (TTM)
0.9301High0.9101Low21.34KVolume0.9301Open0.9251Prev Close19.56KTurnover0.28%Turnover RatioLossP/E (Static)9.49MShares5.000052wk High0.79P/B6.92MFloat Cap0.900052wk Low--Dividend TTM7.59MShs Float1062.2000Historical High--Div Yield TTM2.16%Range %0.9000Historical Low0.9160Avg Price1Lot Size
APRE Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
APRE Orderflow
Unit: --
APRE Orderflow Trend
IntradayDayWeekMonth
No Data
Aprea Therapeutics (APRE) News
Director's Bold Move: Major Stock Purchase in Aprea Therapeutics!
Insider Purchase: Director at $APRE Buys 21,459 Shares
Express News | Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027
Express News | Aprea Therapeutics Announces $3.1 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics (APRE) Stock Forum
$Aprea Therapeutics (APRE.US)$ Reuters
2 mins ago
Aprea Therapeutics Inc - Phase 1 Update Shows Early Disease Control in Hpv+ Patient
2 mins ago
Aprea Therapeutics Inc - Phase 1 Update Shows Early Disease Control in Hpv+ Patient
$Aprea Therapeutics (APRE.US)$
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Wednesday, 25th June at 9:00 am
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Initial Phase 1 clinical update ...
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Wednesday, 25th June at 9:00 am
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Initial Phase 1 clinical update ...
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)